Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Licenses Orchid Cellmark's Nucleotide Extension IP

NEW YORK (GenomeWeb News) – Orchid Cellmark has licensed part of its diagnostic and forensics intellectual property portfolio to Illumina in exchange in for an upfront fee, potential milestone payments, and royalties.

The license for Orchid's single base nucleotide extension technology includes an $850,000 license fee, a potential $150,000 in milestone payments, and royalties from Illumina through any subcontracting agreements. Orchid also will be able to buy certain Illumina products utilizing the patents as a preferred customer.

Orchid retains the rights to use the licensed patents in all fields of use.

"This transaction allows Orchid to work with Illumina to further strengthen our long term competitive position in providing DNA forensic testing services," Thomas Bologna, Orchid Cellmark's president and CEO, said in a statement.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.